An Interview With Miguel Forte, CEO, Bone Therapeutics
By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1
Bone Therapeutics has received regulatory approvals for its clinical trial applications for the next studies of both its lead candidates. In this video, Miguel Forte, CEO of Bone Therapeutics and I talk about the significance of these two studies, his work with ARM and ISCT, as well as COVID-19’s impact on the cell and gene sector.
This website uses cookies to ensure you get the best experience on our website. Learn more